Indicator type	Size of the company	Total
Number of companies carrying out R&D in Biotechnology	Less than 250 employees	1,431
Number of companies carrying out R&D in Biotechnology	250 and more employees	172
Number of companies carrying out R&D in Biotechnology	Total	1,602
% Companies by type of biotechnology used: Genetic Code	Less than 250 employees	27.2
% Companies by type of biotechnology used: Genetic Code	250 and more employees	41.7
% Companies by type of biotechnology used: Genetic Code	Total	28.8
% Companies by type of biotechnology used: Functional Units	Less than 250 employees	37.6
% Companies by type of biotechnology used: Functional Units	250 and more employees	50.1
% Companies by type of biotechnology used: Functional Units	Total	38.9
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Less than 250 employees	19.6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	250 and more employees	36.9
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Total	21.5
% Companies by type of biotechnology used: Bioprocesses	Less than 250 employees	47.2
% Companies by type of biotechnology used: Bioprocesses	250 and more employees	69.4
% Companies by type of biotechnology used: Bioprocesses	Total	49.5
% Companies by type of biotechnology used: Subcellular Organisms	Less than 250 employees	7.5
% Companies by type of biotechnology used: Subcellular Organisms	250 and more employees	18.7
% Companies by type of biotechnology used: Subcellular Organisms	Total	8.7
% Companies by type of biotechnology used: Bioinformatics	Less than 250 employees	26.3
% Companies by type of biotechnology used: Bioinformatics	250 and more employees	31.3
% Companies by type of biotechnology used: Bioinformatics	Total	26.9
% Companies by type of biotechnology used: Nanobiotechnology	Less than 250 employees	11.6
% Companies by type of biotechnology used: Nanobiotechnology	250 and more employees	13.6
% Companies by type of biotechnology used: Nanobiotechnology	Total	11.8
% Companies by type of biotechnology used: Other	Less than 250 employees	17.9
% Companies by type of biotechnology used: Other	250 and more employees	18.4
% Companies by type of biotechnology used: Other	Total	18.0
Companies in which biotechnology activities are: Main and/or exclusive	Less than 250 employees	745
Companies in which biotechnology activities are: Main and/or exclusive	250 and more employees	28
Companies in which biotechnology activities are: Main and/or exclusive	Total	773
Companies in which biotechnology activities are: A secondary business line	Less than 250 employees	223
Companies in which biotechnology activities are: A secondary business line	250 and more employees	56
Companies in which biotechnology activities are: A secondary business line	Total	279
Companies in which biotechnology activities are: A necessary tool for production	Less than 250 employees	463
Companies in which biotechnology activities are: A necessary tool for production	250 and more employees	88
Companies in which biotechnology activities are: A necessary tool for production	Total	550
% Companies by final application areas of biotechnology use: Human Health	Less than 250 employees	49.2
% Companies by final application areas of biotechnology use: Human Health	250 and more employees	41.0
% Companies by final application areas of biotechnology use: Human Health	Total	48.4
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Less than 250 employees	19.5
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	250 and more employees	16.0
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Total	19.1
% Companies by final application areas of biotechnology use: Food Products	Less than 250 employees	27.7
% Companies by final application areas of biotechnology use: Food Products	250 and more employees	38.9
% Companies by final application areas of biotechnology use: Food Products	Total	28.9
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Less than 250 employees	25.0
% Companies by final application areas of biotechnology use: Agriculture and Forestry	250 and more employees	23.1
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Total	24.8
% Companies by final application areas of biotechnology use: Environment	Less than 250 employees	17.8
% Companies by final application areas of biotechnology use: Environment	250 and more employees	21.3
% Companies by final application areas of biotechnology use: Environment	Total	18.2
% Companies by final application areas of biotechnology use: Industry	Less than 250 employees	13.0
% Companies by final application areas of biotechnology use: Industry	250 and more employees	17.7
% Companies by final application areas of biotechnology use: Industry	Total	13.5
R&D personnel in Biotechnology (PP)	Less than 250 employees	11,534
R&D personnel in Biotechnology (PP)	250 and more employees	7,773
R&D personnel in Biotechnology (PP)	Total	19,307
R&D personnel in Biotechnology (PP): Research personnel	Less than 250 employees	7,003
R&D personnel in Biotechnology (PP): Research personnel	250 and more employees	3,776
R&D personnel in Biotechnology (PP): Research personnel	Total	10,779
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Less than 250 employees	4,531
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	250 and more employees	3,998
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Total	8,528
R&D personnel in Biotechnology (PP). Women	Less than 250 employees	6,249
R&D personnel in Biotechnology (PP). Women	250 and more employees	4,905
R&D personnel in Biotechnology (PP). Women	Total	11,155
R&D personnel in Biotechnology (PP). Women: Research personnel	Less than 250 employees	3,719
R&D personnel in Biotechnology (PP). Women: Research personnel	250 and more employees	2,215
R&D personnel in Biotechnology (PP). Women: Research personnel	Total	5,934
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Less than 250 employees	2,530
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	250 and more employees	2,692
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Total	5,222
R&D personnel in Biotechnology (FTE)	Less than 250 employees	8,166.7
R&D personnel in Biotechnology (FTE)	250 and more employees	5,927.0
R&D personnel in Biotechnology (FTE)	Total	14,093.7
R&D personnel in Biotechnology (FTE): Research personnel	Less than 250 employees	5,144.6
R&D personnel in Biotechnology (FTE): Research personnel	250 and more employees	2,929.2
R&D personnel in Biotechnology (FTE): Research personnel	Total	8,073.8
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Less than 250 employees	3,022.0
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	250 and more employees	2,997.9
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Total	6,019.9
R&D personnel in Biotechnology (FTE). Women	Less than 250 employees	4,526.9
R&D personnel in Biotechnology (FTE). Women	250 and more employees	3,778.8
R&D personnel in Biotechnology (FTE). Women	Total	8,305.8
R&D personnel in Biotechnology (FTE). Women: Research personnel	Less than 250 employees	2,784.5
R&D personnel in Biotechnology (FTE). Women: Research personnel	250 and more employees	1,698.0
R&D personnel in Biotechnology (FTE). Women: Research personnel	Total	4,482.6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Less than 250 employees	1,742.4
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	250 and more employees	2,080.8
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Total	3,823.2
Expenditure on internal R&D in Biotechnology (thousands of euros)	Less than 250 employees	829,158
Expenditure on internal R&D in Biotechnology (thousands of euros)	250 and more employees	633,537
Expenditure on internal R&D in Biotechnology (thousands of euros)	Total	1,462,695
1) By type of expenditure: Current expenditure	Less than 250 employees	741,967
1) By type of expenditure: Current expenditure	250 and more employees	605,608
1) By type of expenditure: Current expenditure	Total	1,347,574
1.1) Labour expenditure of research personnel	Less than 250 employees	284,732
1.1) Labour expenditure of research personnel	250 and more employees	185,982
1.1) Labour expenditure of research personnel	Total	470,714
1.2) Labour expenditure of technical and auxiliary personnel	Less than 250 employees	129,850
1.2) Labour expenditure of technical and auxiliary personnel	250 and more employees	128,941
1.2) Labour expenditure of technical and auxiliary personnel	Total	258,791
1.3) Other current expenditure	Less than 250 employees	327,385
1.3) Other current expenditure	250 and more employees	290,684
1.3) Other current expenditure	Total	618,069
2) By type of expenditure: Capital expenditure	Less than 250 employees	87,192
2) By type of expenditure: Capital expenditure	250 and more employees	27,929
2) By type of expenditure: Capital expenditure	Total	115,121
2.1) Land and buildings	Less than 250 employees	13,513
2.1) Land and buildings	250 and more employees	8,365
2.1) Land and buildings	Total	21,877
2.2) Equipment and tools	Less than 250 employees	36,847
2.2) Equipment and tools	250 and more employees	17,744
2.2) Equipment and tools	Total	54,592
2.3) Acquisition of specific R&D software	Less than 250 employees	3,675
2.3) Acquisition of specific R&D software	250 and more employees	998
2.3) Acquisition of specific R&D software	Total	4,673
2.4) Other R&D-specific IP products	Less than 250 employees	33,156
2.4) Other R&D-specific IP products	250 and more employees	822
2.4) Other R&D-specific IP products	Total	33,978
1.1) By origin of funds: Own funds	Less than 250 employees	538,664
1.1) By origin of funds: Own funds	250 and more employees	474,841
1.1) By origin of funds: Own funds	Total	1,013,505
1.2) By origin of funds: Funds from the Business sector	Less than 250 employees	129,527
1.2) By origin of funds: Funds from the Business sector	250 and more employees	76,545
1.2) By origin of funds: Funds from the Business sector	Total	206,072
1.3) By origin of funds: Funds from the Public Administration sector	Less than 250 employees	108,718
1.3) By origin of funds: Funds from the Public Administration sector	250 and more employees	49,989
1.3) By origin of funds: Funds from the Public Administration sector	Total	158,706
1.4) By origin of funds: Funds from the Higher Education sector	Less than 250 employees	615
1.4) By origin of funds: Funds from the Higher Education sector	250 and more employees	0
1.4) By origin of funds: Funds from the Higher Education sector	Total	615
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Less than 250 employees	2,957
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	250 and more employees	6,871
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Total	9,828
1.6) By origin of funds: Funds from the rest of the world	Less than 250 employees	48,678
1.6) By origin of funds: Funds from the rest of the world	250 and more employees	25,290
1.6) By origin of funds: Funds from the rest of the world	Total	73,969
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Less than 250 employees	45,153
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	250 and more employees	51,085
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Total	96,238
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Less than 250 employees	22,799
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	250 and more employees	42,565
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Total	65,364
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Less than 250 employees	22,353
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	250 and more employees	8,521
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Total	30,874
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Less than 250 employees	48.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	250 and more employees	25.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Total	46.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Less than 250 employees	17.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	250 and more employees	16.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Total	17.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Less than 250 employees	26.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	250 and more employees	21.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Total	25.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Less than 250 employees	13.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	250 and more employees	13.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Total	13.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Less than 250 employees	19.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	250 and more employees	10.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Total	18.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Less than 250 employees	18.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	250 and more employees	8.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Total	17.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Less than 250 employees	20.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	250 and more employees	17.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Total	20.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Less than 250 employees	48.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	250 and more employees	39.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Total	47.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Less than 250 employees	54.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	250 and more employees	47.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Total	53.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Less than 250 employees	21.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	250 and more employees	19.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Total	21.6
% Companies with international revenues related to biotechnology activities	Less than 250 employees	21.6
% Companies with international revenues related to biotechnology activities	250 and more employees	27.2
% Companies with international revenues related to biotechnology activities	Total	22.2
% Companies representing international revenues related to biotechnology activities	Less than 250 employees	7.2
% Companies representing international revenues related to biotechnology activities	250 and more employees	1.7
% Companies representing international revenues related to biotechnology activities	Total	2.2
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Less than 250 employees	46.3
% International revenues related to biotechnology activities distributed in: Revenues from the EU	250 and more employees	59.0
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Total	55.2
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Less than 250 employees	53.7
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	250 and more employees	41.0
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Total	44.8
% International revenues related to biotechnology activities by classification: International trade in goods and services	Less than 250 employees	83.3
% International revenues related to biotechnology activities by classification: International trade in goods and services	250 and more employees	88.8
% International revenues related to biotechnology activities by classification: International trade in goods and services	Total	87.2
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Less than 250 employees	2.9
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	250 and more employees	5.3
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Total	4.6
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Less than 250 employees	0.6
% International revenues related to biotechnology activities by classification: Subsidies from external sources	250 and more employees	6.0
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Total	4.3
% International revenues related to biotechnology activities by classification: Other	Less than 250 employees	13.2
% International revenues related to biotechnology activities by classification: Other	250 and more employees	0.0
% International revenues related to biotechnology activities by classification: Other	Total	3.9